Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
ROSETTA Breast-01
A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer
- NCT05227664 ↗
- Active, not recruiting
- Akeso
- Focused
We haven't built an HCP commentary report on ROSETTA Breast-01 (AK117, AK112 and 2 more in Metastatic Triple-negative Breast Cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on ROSETTA Breast-01 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| Podcasts | 3 | |
| Bluesky threads | 2 |
The trial
ClinicalTrials.gov- Official title
- A Phase II Study of AK117/AK112 in Combination With Chemotherapy for Patients With Previously Untreated Metastatic Triple-Negative Breast Cancer
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Metastatic Triple-negative Breast Cancer; Locally Advanced Triple-negative Breast Cancer
- Interventions
- AK117; AK112; Nab paclitaxel; paclitaxel
- Arms
- cohort1(AK117 +AK112 +Nab-Paclitaxel/ Paclitaxel) · Experimental
- cohort2(AK117 +Nab-Paclitaxel/ Paclitaxel) · Experimental
- cohort3(AK112 +Nab-Paclitaxel/ Paclitaxel) · Experimental
- Enrollment
- 120 (estimated)
- Primary outcomes
- Objective response rates (ORR)
- Number of participants with adverse events (AEs)
- Sponsor
- Akeso
- Start
- Mar 23, 2022
- Primary completion
- Dec 30, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT05227664 · updated Mar 16, 2026
Publications
linked from the registry- Shao X, Tian C, Chen Z, Huang J, Wang Y, Sun T, Yi T, Wu Y, Sun W, Yu X, Wang ZM, Li B, Xia Y, Wang X, Ouyang Q. First-line PD-1/VEGF bispecific antibody plus chemotherapy in triple-negative breast cancer: a phase 2 trial. Nat Med. 2026 Aug 12. doi: 10.1038/s41591-026-04564-7. Online ahead of print. PubMed 42587052